11/19/2012

A European Medicines Agency committee has recommended approval of Sanofi and Zealand Pharma's Lyxumia as a therapy for type 2 diabetes. Sanofi and Regeneron Pharmaceuticals' anti-angiogenic agent Zaltrap also won approval recommendation from the Committee for Medicinal Products for Human Use as a treatment for advanced colorectal cancer with chemotherapy.

Full Story:
CNBC, Bloomberg

Related Summaries